PARD3B

Across TCGA pan-cancer cohorts, PARD3B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PARD3B data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PARD3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARD3B expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

SKCM, LIHC, and STAD are the cancer types where PARD3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.360	0.792	.002	13	view →
LIHC	DFS	Median	All	0.100	0.557	<.001	12	view →
STAD	OS	Median	All	0.827	0.407	.035	9	view →
GBM	OS	Median	All	0.005	0.416	<.001	6	view →
SCLC	OS	Median	All	0.192	0.669	<.001	6	view →
READ	DFS	Median	All	0.158	0.544	.018	3	view →
LUAD	OS	Median	All	0.662	0.817	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PARD3B–SKCM (OS)

Open the SKCM breakdown →